Proteomic Insights Into Causality & WAL0921 Treatment Effects in suPARDriven CKD
Time: 2:30 pm
day: Conference Day One
Details:
- Further evidence for suPAR driven progression in rare kidney disease indications
- WAL0921 as a suPAR reducing agent in kidney therapy
- Proteomic data insights into mechanism of action of anti-suPAR treatment
